603127 昭衍新藥
按盤價 
13.220 -0.130 (-0.974%) | 2024/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 324,809 | -12.07% | 2,376,487 | 2,267,971 | 1,516,680 | 1,075,905 | |
| 減：營業總成本 | 293,295 | 11.60% | 1,622,010 | 1,418,766 | 1,086,978 | 804,306 | |
| 其中:營業成本 | 218,157 | 22.26% | 1,363,701 | 1,181,660 | 777,558 | 523,092 | |
| 財務費用 | (28,011) | 12.95% | (151,091) | (154,682) | (19,156) | 2,477 | |
| 資產減值損失 | (26,264) | 6,188.21% | (31,232) | (2,792) | (1,331) | (1,510) | |
| 公允價值變動收益 | (310,013) | -414.92% | (245,642) | 349,567 | 157,777 | 58,946 | |
| 投資收益 | 6,972 | 1,256.11% | 9,628 | 13,022 | 17,000 | 1,524 | |
| 其中：對聯營企業和合營企業的投資收益 | (559) | -27.43% | (3,069) | (2,691) | (426) | -- | |
| 營業利潤 | (293,008) | -236.68% | 507,096 | 1,225,639 | 642,889 | 361,118 | |
| 利潤總額 | (293,130) | -236.77% | 506,950 | 1,240,002 | 642,004 | 360,572 | |
| 減：所得稅費用 | (19,766) | -174.26% | 115,398 | 166,802 | 85,587 | 46,944 | |
| 淨利潤 | (273,364) | -245.63% | 391,553 | 1,073,200 | 556,416 | 313,628 | |
| 減：非控股權益 | (1,141) | 2,201.76% | (5,440) | (1,057) | (1,043) | (1,386) | |
| 股東淨利潤 | (272,222) | -244.98% | 396,993 | 1,074,257 | 557,460 | 315,014 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.360 | -244.00% | 0.530 | 1.440 | 1.080 | 1.000 | |
| 每股派息 (元) * | -- | -- | 0.160 | 0.400 | 0.360 | 0.350 | |
| 每股淨資產 (元) * | 10.659 | -31.66% | 11.040 | 15.277 | 18.720 | 5.390 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 02/07/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
